The response to checkpoint inhibitors was predominantly mediated through interactions of anti-PD-L1 antibodies with PD-L1 on host myeloid cells, which promotes T cell activation to mount an anti-tumor response [105]. The gene discussed is CD274; the disease is neoplasm.